Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: Comparison of Prophylaxis and Therapy by van Elsas, Andrea et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/08/481/09 $5.00
Volume 194, Number 4, August 20, 2001 481–489
http://www.jem.org/cgi/content/full/194/4/481
 
481
 
Elucidating the Autoimmune and Antitumor
Effector Mechanisms of a Treatment Based on
Cytotoxic T Lymphocyte Antigen-4 Blockade in 
Combination with a B16 Melanoma Vaccine:
Comparison of Prophylaxis and Therapy
 
Andrea van Elsas,
 
1, 2 
 
Roger P.M. Sutmuller,
 
2 
 
Arthur A. Hurwitz,
 
1
 
 
Jennifer Ziskin,
 
1
 
 Jennifer Villasenor,
 
1
 
 Jan-Paul Medema,
 
2
 
Willem W. Overwijk,
 
3
 
 Nicholas P. Restifo,
 
3 
 
Cornelis J.M. Melief,
 
2 
 
Rienk Offringa,
 
2 
 
and James P. Allison
 
1
 
1
 
Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 
94720
 
2
 
Department of Immunohematology and Bloodbank, Leiden University Medical Center, 2300 RC 
Leiden, Netherlands
 
3
 
Surgery Branch, National Institutes of Health, Bethesda, Maryland 20892
 
Abstract
 
We have previously shown that small B16 melanomas can be successfully treated using a com-
bination of anti–cytotoxic T lymphocyte antigen (CTLA)-4 monoclonal antibody with a gran-
ulocyte/macrophage colony-stimulating factor (GM-CSF) producing irradiated tumor cell vac-
cine. Regression of tumors results in long-lasting immunity and is frequently accompanied by
autoimmune depigmentation. Here we examine the cellular and molecular mechanisms of this
combined treatment. Histological examination of depigmented lesions revealed infiltration of
polymorphonuclear cells and deposition of antibody. The combination therapy also induced
tumor rejection and skin depigmentation in B cell–deficient and in CD4
 
 
 
 T cell–depleted
mice. Both effects of the treatment absolutely required CD8
 
 
 
 T cells. Analysis of the response
in successfully treated mice revealed elevated levels of CD8
 
 
 
 T cells specific for a nonameric
peptide consisting of residues 180–188 of the melanocyte differentiation antigen tyrosinase-
related protein (TRP)2. There was no evidence of reactivity to the melanocyte antigens gp100,
tyrosinase, Mart1/MelanA, or TRP1. Fas–FasL interactions and perforin played a role in
mounting the effector response, whereas the tumor necrosis factor pathway was not required.
The cellular requirements for tumor rejection in this therapeutic setting were strikingly differ-
ent from those in a prophylactic setting. In particular, if mice received a prophylactic vaccine
consisting of anti–CTLA-4 and B16–GM-CSF before tumor challenge, full protection was ob-
tained even in the absence of CD8
 
 
 
 T cells. Our data demonstrate that therapeutic autoreac-
tive CD8
 
 
 
 T cell responses can effectively be generated in tumor-bearing mice and stresses the
value of studying tumor immunity in a therapeutic rather than a prophylactic setting.
Key words: immunotherapy • prophylaxis • T lymphocyte • TRP-2 • depigmentation
 
Introduction
 
In the past decade, a wealth of tumor-associated antigens
have been identified that provide targets for CTL and
CD4
 
 
 
 T cells in cancer patients (for reviews, see references
1 and 2). Human melanoma has provided a paradigm in
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this respect, demonstrating that such tumor antigens can be
derived from tissue-specific self-antigens, from tumor-spe-
cific mutated proteins, or from aberrantly expressed pro-
teins that normally function only during embryonic de-
velopment. Depigmentation or vitiligo (spontaneous or
treatment related) appears to correlate with favorable prog-
nosis and successful rejection of metastatic melanoma, indi-
cating that self-antigens might play a role in antitumor re-
sponses (3,4). Melanocyte proteins involved in pigment
synthesis have frequently been shown to be targets for
CTLs, CD4
 
 
 
 T cells, and antibodies in melanoma patients
or in healthy donors. In vitiligo and melanoma patients, tu-
mor-associated and potentially autoimmune T cell–medi-
ated reactivity can be linked directly to destruction of pig-
mented cells in the skin (5, 6). As these pigmentation
antigens are expressed by most melanomas even in ad-
vanced stages, they are considered to be good candidate
targets for specific immunotherapy, provided that damage
to healthy tissue is limited. Importantly, immunological
tolerance to these melanocyte antigens is clearly incomplete
or absent providing the rationale for clinical testing of vac-
cines consisting of pigmentation proteins or their T cell
epitopes. A satisfactory animal model for melanoma treat-
ment is essential for assessment of the risks and require-
ments for such immunotherapy to be successful.
T cell responses are regulated not only by antigen recep-
tor signals, but also by positive and inhibitory costimulatory
signals mediated by the interactions of CD28 and CTLA-4,
respectively, with their cognate B7 ligands on antigen-pre-
senting cells (7). We and others have shown that adminis-
tration of antibodies to block the inhibitory effects of
CTLA-4 can enhance antitumor responses in several mu-
rine tumor models (8–14). Of particular relevance to mela-
noma is our demonstration that mice carrying a small load
of B16 melanoma cells can be successfully treated with a
combination vaccine consisting of GM-CSF–producing,
irradiated B16 cells and CTLA-4 blockade (13). Approxi-
mately 60% of the surviving mice developed lesions of de-
pigmentation reminiscent of vitiligo. B16 therapy in this
model absolutely requires the presence of CD8
 
 
 
 cells. Our
finding that the combination therapy was CD8 dependent
and resulted in depigmentation was especially interesting in
light of previous studies using the GM-CSF–producing
B16 vaccine as a single agent (15). In these studies it was
found that the vaccine was capable of inducing prophylac-
tic immunity mediated mainly by CD4
 
 
 
 T cells with no
requirement for CD8
 
 
 
 T cells (15, 16). Also, this cell-based
vaccine by itself was not effective in a therapeutic setting,
and depigmentation was not reported even when prophy-
lactic immunity had been successfully obtained.
We now report an extensive examination of the mecha-
nisms involved in the generation of immunity to B16 us-
ing the combination therapy. We have found that neither
CD4
 
 
 
 T cells, nor antibody responses are required for
treatment effect, as tumor rejection and depigmentation
occur in B cell–deficient mice. Both the Fas and perforin
pathways are required, but TNF-
 
 
 
 is dispensable. T cells
responding to the melanocyte differentiation antigen ty-
 
rosinase-related protein 2 (TRP-2)
 
*
 
 antigen were found in
spleen cell cultures and in peripheral blood from depig-
mented mice. Depletion studies confirm that CD8
 
 
 
 T cells
are required for both the antitumor effect and depigmenta-
tion in a therapeutic setting. In the setting of prophylaxis,
CD8
 
 
 
 T cells are not required for tumor immunity, but
are required for depigmentation. These findings demon-
strate that the cellular mechanisms involved in protection
against subsequent tumor challenge are different from
those observed in a therapeutic setting. This underscores
the added value of studying tumor immunity in tumor-
bearing subjects.
 
Materials and Methods
 
Mice.
 
C57Bl/6 female mice, B cell–deficient (from The Jack-
son Laboratory), MHC class I
 
 
 
 (
 
 
 
2m
 
 
 
/
 
 
 
), and class II–deficient
mice (I-A
 
  
 
/
 
 
 
; Taconic) as well as perforin-deficient, TNF-
 
 
 
knockout, 
 
gld
 
, and 
 
lpr
 
 mice (all bred into the C57Bl/6 back-
ground) were maintained and treated in accordance with institute
guidelines. Mice were used for tumor experiments when 8–16
wk old.
 
Antibodies and Cell Lines.
 
Generation and purification of
anti–CTLA-4 (9H10) has been described previously (17). Con-
trol hamster IgG, control rat IgG, and control mouse IgG were
purchased from Jackson ImmunoResearch Laboratories. Anti–
H-2D
 
b
 
, anti–H-2K
 
b
 
, anti-CD4 (GK1.5), anti-CD8 (2.43), anti-
NK1.1 (PK136), and anti-Lyt2.1 (116.3) were isolated from hy-
bridoma culture supernatants, or grown as ascites by standard pro-
cedures. Antisera specific for TRP-1 (TA99) and TRP-2
(
 
 
 
PEP8) were generously provided by Alan Houghton (Memo-
rial Sloan-Kettering Institute, New York, NY) and Vincent
Hearing (National Institutes of Health, Bethesda, MD). The
C57Bl/6-derived tumor cell lines B16-BL6, B16-F0, B16-F10
(obtained from I. Fidler, M.D. Anderson Cancer Center, Hous-
ton, TX), EL-4, MC38, RMA-S, as well as the immortalized
dendritic cell line DC2.4 (18) were cultured in DMEM or
IMDM supplemented with 1 U/ml penicillin, 1 
 
 
 
g/ml strepto-
mycin, 50 
 
 
 
g/ml gentamycin, 2 
 
 
 
M 
 
l
 
-glutamine, 20 
 
 
 
M
 
 
 
-mercaptoethanol, and 8% fetal calf serum (hereafter referred to
as CM). GM-CSF–producing B16-BL6 clones BL6/GM-E,
BL-6/GM-18, and the CD80-expressing variant B16-BL6/B7.1
(13) were similarly cultured in CM.
 
Tumor Challenge and Treatment.
 
Subcutaneous tumor challenge
and treatment experiments were performed as described previ-
ously (13). Briefly, mice were challenged subcutaneously with
1–2 
 
 
 
 10
 
4
 
 B16-BL6 cells in PBS. At the same day or later as indi-
cated, treatment was initiated by injecting 10
 
6
 
 irradiated (16,000
rad) GM-CSF–producing cells (in PBS) subcutaneously into the
left flank, and repeated 3 and 6 d later. The vaccine consisted of a
1:1 mixture of clones BL6/GM-E and BL6/GM-18. Treatment
with 9H10 or control hamster IgG started 3 d later. Antibodies
were delivered intraperitoneally at 100 
 
 
 
g in PBS, followed by
two injections of 50 
 
 
 
g 3 and 6 d later. Tumor growth was
scored by measuring perpendicular diameters. Mice were killed
when the tumors displayed severe ulceration or reached a size of
250 mm
 
2
 
. Depletion of lymphoid subsets was done as described
earlier, starting a week before tumor challenge. Depletions were
maintained for at least 3 wk by weekly injecting the appropriate
 
*
 
Abbreviations used in this paper: 
 
aa, amino acid(s); PI, propidium iodide;
TRP, tyrosinase-related protein. 
483
 
van Elsas et al.
 
antibodies. Prophylactic experiments were done as follows. Mice
were immunized by injecting 10
 
6
 
 irradiated GM-CSF–producing
B16-BL6 cells subcutaneously on days 
 
 
 
12, 
 
 
 
9, and 
 
 
 
6, in
combination with anti–CTLA-4 given on days 
 
 
 
9, 
 
 
 
6, and 
 
 
 
3
(100, 50, and 50 
 
 
 
g per mouse). On day 0, mice were challenged
with B16-BL6. Depletions of lymphoid subsets in the prophylac-
tic model were started at day 
 
 
 
3 by three daily injections of 500
 
 
 
g of depleting antibody, and maintained for 3 wk by biweekly
administration of antibody.
 
Generation of T Cell Cultures from Spleen and IFN-
 
 
 
 Release As-
says.
 
Spleens were harvested from mice rejecting B16-BL6 and
restimulated in vitro with B16-BL6/B7.1 or a mixture of B16-F0
and the dendritic cell line DC2.4 after overnight coculture. 5 
 
 
 
10
 
6
 
 spleen cells were mixed with 10
 
5
 
 irradiated (16,000 rad) stim-
ulator cells and recombinant human IL-2 was added to a final con-
centration of 30 IU/ml. After 7 d, cells were collected and puri-
fied by Histopaque gradient centrifugation. Live cells (2.5 
 
 
 
 10
 
5
 
per well) were stimulated with target cells (5 
 
 
 
 10
 
4
 
 per well) in
96-well round-bottom plates for 24 h, after which supernatant was
collected and tested for the presence of IFN-
 
 
 
 by sandwich ELISA
(BD PharMingen). As target cells, several variants derived from
parental line B16-F0, as well as the nonpigmented colon tumor
line MC38 were used. MC38 cells were transduced as described
earlier (19) with recombinant vaccinia virus (rVV) expressing mu-
rine Pmel-17/gp100, Mart-1/Melan-A, tyrosinase, gp75/TRP-1,
TRP-2, or 
 
 
 
-galactosidase to serve as targets in a cytokine release
assays. As a control, wild-type vaccinia (VVwt) was used in each
experiment. Peptide pulsed targets were prepared by washing
MC38 cells threefold in serum-free media, and incubating up to 2 
 
 
 
10
 
6
 
 cells per ml with 10 
 
 
 
g/ml peptide, for 90 min at 37
 
 
 
C. Un-
bound peptide was washed away by three washes with serum-free
media, after which cells were diluted in CM and dispensed into
96-well plates for the cytokine release assays.
 
Peptide Selection, Synthesis, and Testing.
 
Peptides were selected
from the murine TRP-2 protein sequence based on the published
motifs for binding to H-2K
 
b
 
 or H-2D
 
b
 
. For H-2K
 
b
 
, both 8- and
9-mer sequences were included, whereas for H-2D
 
b
 
 this included
9- and 10-mer sequences. Peptides were synthesized by standard
Fmoc chemistry, and purity was checked by HPLC. Fractions
routinely contained 
 
 
 
95% of the expected sequence. Peptides were
dissolved in DMSO at 50 mg/ml, and diluted into PBS for bind-
ing assays and peptide pulsing onto MC38 or RMA-S cells. Pep-
tide binding to H-2K
 
b
 
 and H-2D
 
b
 
 was determined as follows.
RMA-S cells, precultured at 26
 
 
 
C for 48 h, were washed three
times in serum-free media and incubated with peptide at 26
 
 
 
C for
2 h, followed by 2 h at 37
 
 
 
C. Cells were washed with ice-cold
PBS/0.5% BSA, stained for expression of H-2K
 
b
 
 and H-2D
 
b
 
, and
analyzed on a FACScan™ (Becton Dickinson).
 
Tetramer Staining.
 
TRP-2
 
180–188
 
/K
 
b
 
 tetramers labeled with al-
lophycocyanin (APC) were a gift from Ton Schumacher and
John Haanen (Netherlands Cancer Institute, Amsterdam, Neth-
erlands). Blood leukocytes were collected in heparin coated tubes
and erythrocytes were lysed using standard procedures. Remain-
ing leukocytes were washed and incubated with FITC-labeled
CD8
 
 
 
-specific antibodies and APC-labeled tetramers in PBS/1%
BSA, and after two washes in PBS/1% BSA analyzed in PBS/1%
BSA/1 
 
 
 
g/ml propidium iodide (PI). PI-negative cells were
gated for the lymphocyte population and further analyzed.
 
Histology.
 
Formalin-fixed, paraffin-embedded sections were
prepared from the depigmenting skin and control skin and
stained with hematoxylin and eosin. Alternatively, sections were
deparaffinized and reacted with biotinylated anti–mouse IgG/
IgM antibody followed by streptavidin-peroxidase, and the reac-
 
tion visualized with diaminobenzidine (brown precipitate). Sec-
tions were counterstained with hematoxylin.
 
Results
 
Lack of Functional B Cell Responses Does Not Impair B16
Treatment or Depigmentation.
 
Both tumor rejection and
depigmentation occurred in mice bearing B16 tumors after
combination therapy with anti–CTLA-4 and GM-CSF
B16 vaccine, even in the absence of CD4
 
 
 
 T cells (13).
This suggested that neither CD4 T cell help, nor by exten-
sion antibody responses, were required for either effect.
We examined the depigmented skin of successfully treated
mice for hallmarks of autoimmunity. Polymorphonuclear
cells were clearly detected infiltrating the dermis concen-
trating around the hair follicles (Fig. 1). Also, pigmented
granules were found deposited around the hair follicles and
Ig deposits were detected (Fig. 1). These hallmarks of au-
toimmune response were absent from nonaffected skin in
these depigmented mice and in control animals. Antibody
responses directed against melanocyte antigens such as
TRP-1/gp75 were shown previously to be involved in de-
pigmentation in humans and in mice (20, 21). However,
we were unable to detect antibodies against TRP1/gp75 or
other B16 specific proteins by staining intact or permeabi-
lized cells using sera collected from depigmented mice (data
not shown). As a definitive determination of the role of B
cells in tumor rejection and depigmentation using our
combination therapy of B16, we attempted to treat B16 tu-
mors in B cell knockout (
 
 
 
MT) mice bred onto the
C57Bl/6 background. At the usual tumor dose of 10
 
4
 
 cells
per mouse, B cell–deficient mice displayed 
 
 
 
75% tumor
take (Fig. 2 A). The reduced tumor take compared with
wild-type mice is consistent with earlier studies showing
that B cell–deficient mice displayed enhanced immunity to
several transplantable tumor cell lines (22). All B6.
 
 
 
MT
mice receiving combination therapy rejected their tumors
and most of these (6 of 9) displayed signs of depigmentation
within 4 wk after challenge (Fig. 2 B). These results dem-
onstrate that B cells are not required to initiate or maintain
immunity against B16 or normal melanocytes in this model
and further suggest that the antibody deposition detected in
the skin of depigmented wild-type mice may be a second-
ary effect of the autoimmune response.
 
Role of Fas, Perforin, and TNF-dependent Pathways of Kill-
ing in Mounting a Productive Immune Response to B16.
 
The
perforin, Fas/Fas-L, or TNF-
 
 
 
–dependent pathways of
killing have all been implicated in controlling tumor out-
growth (23–25). To delineate the relative roles of these
pathways in the combination therapy of B16, we tested our
combination B16 vaccine protocol in mice deficient in
perforin, TNF-
 
 
 
, Fas (
 
lpr
 
), or Fas-L (
 
gld
 
) functions bred
into the B6 background. The results are presented in Table
I. In the absence of treatment all mice developed B16 tu-
mors appearing macroscopically between days 10 and 12
and growing at comparable rates. The incidence and rate of
tumor growth in 
 
lpr
 
 or 
 
gld
 
 receiving the combination ther- 
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apy was similar to untreated controls, demonstrating that
functional Fas/Fas-L interactions are necessary for the ther-
apeutic effects of the treatment. In the absence of perforin,
B16 tumor outgrowth was delayed by the combination
therapy, but all of the mice eventually succumbed to tu-
mor. In contrast, all TNF-
 
 
 
–deficient mice rejected their
tumors upon combination treatment, and 4 of the 7 survi-
vors developed autoimmune depigmentation, demonstrat-
ing that this pathway of killing is not required for therapeu-
tic effect. These results underscore the importance of both
Fas/FasL interactions and perforin for obtaining tumor re-
jection in our B16 model of combination therapy.
 
Definition of TRP-2180–188 as a T Cell Target in Mice Re-
ceiving Combination Treatment. Depletion studies had indi-
cated that successful treatment of B16 by the combination
therapy required CD8  T cells (13; see Fig. 5). As most of
the surviving mice developed depigmentation, we reasoned
that melanocyte antigens involved in pigment synthesis
could be serving as targets for cytotoxic T cells. We gener-
ated short-term T cell cultures by stimulating spleen cells
with a mixture of a syngeneic dendritic cell line DC2.4 and
B16 (cocultivated for 24 h). These cultures were tested for
reactivity against syngeneic MC38 cells that had been
transduced with rVV expressing each of the aforemen-
Figure 1. Histological signs of
autoimmunity in depigmented
skin of mice surviving B16 chal-
lenge. Transverse sections from
depigmented (B and D) or unin-
volved skin (A and C) from the
same mouse were stained with
hematoxylin and eosin to detect
cellular infiltrate (A and B), or
stained for the presence of Ig
deposition (C and D) following
procedures described in Materi-
als and Methods.
Figure 2. Rejection of B16-BL6 and subsequent depigmentation in B /  mice, after combination treatment with anti–CTLA-4 and B16/GM-CSF. B
cell–deficient mice were challenged with B16-BL6 and treated following the general scheme as outlined before. Tumor-free survival (A) as well as signs
of autoimmune depigmentation were scored. Of nine B /  mice receiving combination treatment, six developed depigmentation of which an example
is shown (B). wt, wild-type.485 van Elsas et al.
tioned melanocyte antigens. T cell cultures from mice re-
jecting B16-BL6 subcutaneous tumor challenge (mouse
12K54), or B16-F10 lung metastases (mouse 44C1; see, for
example, Fig. 4 in reference 13), displayed a restricted reac-
tivity toward the TRP-2 antigen (Fig. 3).
The murine TRP-2 protein sequence was scanned for
potential Kb or Db binding peptides. Over 60 peptides (8
to 10 amino acids [aa]) were synthesized and tested for
binding to Kb or Db on RMA-S cells (Table II). Peptides
were pulsed onto RMA-S cells and tested for the ability to
stimulate splenic T cells from depigmented mice that had
rejected B16 tumors. Strong stimulation was found only
with a single peptide comprised of aa 180 to 188 of TRP-2,
SVYDFFVWL (Table II), a nonamer variant of a previ-
ously identified TRP-2–derived B16 epitope (26). Inter-
estingly, this variant had been shown to bind to H-2Kb
with much higher affinity than the 8-mer minimal
epitope, which may explain why we only detected reactiv-
ity against the nonamer (27). Mice rejecting established
B16 tumors upon combination treatment were evaluated
for the presence of TRP-2–specific CD8  T cells in pe-
ripheral blood samples using TRP-2180–188/Kb tetramers.
Indeed, a clearly detectable fraction of CD8   cells (1.7%)
was stained using the TRP-2/Kb–specific reagent (Fig. 4).
As these cells were not detected in significant numbers
( 0.2%) in untreated mice, this implies that the combina-
tion treatment of CTLA-4 blocking antibody plus GM-
CSF producing whole cell vaccine was responsible for in-
ducing this reactivity.
Differential Requirements for Lymphocyte Subsets in Prophy-
lactic versus Therapeutic B16 Model. In our combination ther-
apy model, CD8  and NK1.1  cells were required for suc-
cessful treatment of B16 melanoma (13). Previous studies
using the GM-CSF vaccine alone had clearly demonstrated
a requirement for CD4  T cells and Th2 cytokines for pro-
tection against subsequent challenge with B16 cells (16).
CD8  cells were shown to contribute to the response, but
were not essential. As these two studies differed not only in
the use of anti–CTLA-4 but also in the setting of the treat-
ments, we compared the requirements for CD4 CD8 
cells and NK1.1  cells in prophylactic and therapeutic ap-
plication of the combination treatment protocol.
Confirming our previous findings in the therapeutic set-
ting, depletion of CD8  and NK1.1  cells hampered rejec-
tion of small established tumors (Fig. 5 B). CD4  T cells
were not required or either tumor rejection or depigmen-
tation. In fact, the data suggest that the combination ther-
apy might be slightly more effective in inducing tumor re-
jection and depigmentation when CD4  T cells are not
present. This suggests that CD4  T cells might play a role
in inhibiting the antitumor response. This possibility has
been examined in another study (27a).
In contrast to therapy, in the prophylactic setting full
protection to subsequent challenge was conferred by the
combination treatment in the absence of either CD4, CD8,
or NK1.1  cells at the time of B16 challenge (Fig. 5 A).
Thus, CTLA-4 blockade in combination with the prophy-
lactic application of the GM-CSF vaccine allows the gener-
ation of an effective antitumor response that is not depen-
dent on any single lymphocyte subset, including CD4  T
Table I. B16 Treatment Fails in Mice Lacking Perforin, Fas, or 
Fas-L Expression
Tumor rejection (rejecting/challenged)
Wild-type Perforin /  lpr gld TNF-  / 
No treatment 0/8 0/5 0/5 0/6 0/6
Anti–CTLA-4  
B16/GM-CSF 6/9 0/6 0/5 0/7 7/7
Mice were immunized and challenged with tumor as described in
Materials and Methods. Tumors in wild-type mice became palpable by
10–14 d after implant. Euthanasia or death usually occurred by 50 d.
Surviving mice were followed for signs of tumor growth for about 50 d.
Figure 3. T cell lines derived from mice surviving B16-BL6 challenge
react to VV-TRP-2 transduced targets. T cell lines established from mice
surviving B16-BL6 challenge after combination therapy were tested for
reactivity toward B16 variants BL6, F0, and F10, as well as MC38 cells
expressing murine pigmentation antigens gp100, tyrosinase, Mart-1,
TRP-1, and TRP-2 after transduction with recombinant vaccinia virus.
Reactivity was quantified by measuring IFN-  release after 24 h cocul-
ture of T cells and targets. T cell culture 12K54 (top) was derived from a
mouse surviving B16-BL6 subcutaneous tumor upon combination treat-
ment, whereas culture 44C1 (bottom) was established after treatment of
B16-F10 lung metastases (see text).486 Mechanism of Therapeutic B16 Vaccination Enhanced by Anti-CTLA4
cells. Interestingly, despite the fact that the CD8  T cell
subset was not required for tumor rejection in the prophy-
lactic setting, CD8  T cells were essential for depigmenta-
tion. This showed that in prophylaxis, in contrast to ther-
apy, effective tumor immunity could be generated without
subsequent autoimmunity.
Discussion
CD8  T Cells, but Not B Cells or CD4  T Cells, Are Re-
quired for Tumor Rejection and Associated Autoimmunity after
Combination Therapy. The results presented here confirm
our earlier report that CD4  T cells are not required for
successful therapy of B16 using the B16–GM-CSF and
anti–CTLA-4 combination therapy and, in addition, dem-
onstrate that B cells are also dispensable for both tumor re-
jection and depigmentation. These findings are of interest
for several reasons. One concerns the mechanism of depig-
mentation. The fact that tumor rejection was followed by
autoimmune depigmentation suggests that a major com-
ponent of the immune response was directed against anti-
gen(s) shared between the tumor, vaccine, and normal
melanocytes. Several previous studies have implicated an-
tibody responses to pigmentation antigens as playing a
central causal role in vitiligo or melanoma-associated hy-
popigmentation (20, 21, 28–31). Although we detected
Table II. TRP-2180–188 Encodes the Optimal Epitope Recognized 
by T Cells Derived from Treated Mice
Binding tob 
aa (TRP-2) Sequence Motifa Kb Db
Recognitionc
(IFN-  ng/ml)
180 SVYDFFVWL Kb    73.4
181 VYDFFVWL Kb    11.3
185 FVWLHYYSV Kb    10.3
186 VWLHYYSV Kb    1.3
OVA8 Kb       Not tested
The data shown are only for the Kb binding peptides relevant to the
actual epitope that stimulate T cells from the immunized mice. The data
concerning the other Kb and Db peptides can be found on the lab
website: http://mcb.Berkeley.edu/labs/allison.
aPeptides were selected from the murine TRP-2 sequence using the
motif searches at the following internet address: http://bimas.
dcrt.nih.gov/molbio/hla_bind/ (39), and compared to results obtained
from an in-house motif search program. Peptide sequences containing
at least one anchor and scoring high in both programs were selected for
synthesis and further analysis.
bBinding to H-2Kb or H-2Db was determined by incubating RMA-S
cells with a peptide dilution range (100–0.1  g/ml) and detection by
Db- or Kb-specific antibodies. Binding was scored as follows: no bind-
ing ( ), significant binding at 10  g/ml ( ), at 1  g/ml (  ), or at
0.1  g/ml (   ).
cPeptides were pulsed onto RMA-S cells and recognition was tested by
determining IFN-  release in short-term splenic T cell cultures (see, for
example, Fig. 4).
Figure 4. Detection of TRP-2180–188/Kb reactive CD8  T cells in PBL
of mice receiving combination treatment. PBL taken at day 17 from mice
challenged with B16-BL6 receiving no further treatment (left) or treated
with anti–CTLA-4 plus B16/GM-CSF (right) were gated for live cells in
the presence of PI, and CD8   TRP-2180–188/Kb tetramer-positive T
cells were analyzed. Indicated in the top right quadrant is the percentage
of CD8b  T cells that are detected with the tetramer reagent.
Figure 5. Differential requirements for lymphoid subpopulations in
therapeutic vs. prophylactic treatment of B16. C57Bl/6 mice received
treatment with anti–CTLA-4 plus B16/GM-CSF vaccine started either
before challenge with B16-BL6 (“prophylaxis,” top graph), or simulta-
neously with challenge (“treatment,” bottom graph). Before tumor chal-
lenge mice were depleted from CD4 , CD8 , or NK1.1  cells or treated
with control IgG (as described in Materials and Methods). The percent-
age of mice rejecting the tumor was scored (total of each bar) as well as
the fraction of surviving mice developing depigmentation, as indicated by
the unfilled (“depigmented”) part of each bar. This is a representative of
two experiments.487 van Elsas et al.
the presence of Ig depositions in the depigmented skins of
surviving wild-type B6 mice, we did not find evidence of
specific B cell responses toward pigmentation antigens ex-
pressed by B16. Our findings do not rule out the possibil-
ity that the antibody deposited on depigmentation lesions
in wild-type mice is secondary to the antitumor and au-
toimmune response and is the consequence of a process
similar to intermolecular epitope spreading. However, the
fact that B cell knockout mice (Fig. 2) and MHC class II / 
mice (unpublished data) develop depigmentation after re-
ceiving combination therapy and rejecting tumor clearly
demonstrates that antibody is not required for either effect.
This, together with the demonstration that CD8  T cells
are absolutely required for depigmentation in either the
therapeutic or prophylactic settings in our system, indi-
cates that this effect involves recognition of MHC class
I–restricted peptides present in or derived from normal
melanocytes.
A second important point made by the data is that there
is no requirement for CD4  T cell help in the induction of
either tumor rejection or depigmentation in the combina-
tion therapy. The basis for this is not clear, but may reflect
an effect of CTLA-4 on the threshold of costimulation
needed for activation of naive CD8  T cells. It is tempting
to speculate that in this system, blockade of CTLA-4/B7
interactions allows effective activation and expansion of
CD8  T cells even by dendritic cells that have not been li-
censed by activated CD4  T cells (32–34). This possibility
is supported by a previous report that CTLA-4 blockade
resulted in the enhancement of CD8  T cell responses to
peptide independently of CD4  T cell help (35). What-
ever the basis for the effect, it is clear that the addition of
anti–CTLA-4 antibody frees the GM-CSF–transduced tu-
mor cell vaccine from an absolute dependence on CD4  T
cells (16).
A third point that emerges from the data is that tumor
rejection requires both the perforin and the Fas pathways of
killing (Table I). The importance of Fas in immune control
of tumors has only been recognized recently (23, 36, 37)
and was confirmed in our therapy model. As both lpr and
gld mice displayed impaired therapeutic responses in our
treatment model, Fas/FasL interactions may primarily be
required during the generation of an effective immune re-
sponse. From these data we cannot rule out the possibility
that Fas/FasL interactions are also involved in direct effec-
tor mechanisms controlling tumor outgrowth. In perforin-
deficient mice, B16 tumors initially displayed delayed out-
growth after combination treatment. Ultimately, however,
all the mice succumbed to progressive B16 tumors. This
suggests that the first wave of immune effector cells might
not depend on perforin for their immune control of tumor
growth, whereas ultimately both Fas/Fas-L and perforin
dependent lytic pathways are required for tumor rejection
(possibly involving both T cells and NK cells).
CD8  T Cell Response toward TRP-2180–188 Generated by
Combination Therapy. As both antitumor and autoimmu-
nity were dependent on the presence of CD8  cells (e.g.
Fig. 5), we sought to identify the antigenic target(s) of this
response. In studies on CTL reactivity against human mela-
noma, several candidate antigens were identified, including
tyrosinase, Pmel-17/gp100, Melan-A/Mart-1, TRP-1, and
TRP-2. In response to combination therapy, a T cell pop-
ulation directed to TRP-2 is specifically activated and ex-
panded in our model (Figs. 3 and 4). Mice surviving for up
to 18 mo after the initial subcutaneous or intravenous tu-
mor challenge only reacted against TRP-2 of the mela-
noma differentiation antigens tested. It is unlikely that this
would reflect CD4 T cell reactivity against the TRP-2–
derived nonamer, as the vaccinia-infected or peptide-
pulsed target cells (MC38 or RMA-S) are MHC class II
negative. The murine TRP-2181–188 epitope, VYDFFVWL,
presented by H-2Kb was previously characterized as a B16
tumor rejection antigen (26). In our system, only minimal
reactivity against the octamer epitope was found. Instead,
we found potent reactivity toward a nonamer variant of
this epitope SVYDFFVWL (TRP-2180–188). This result is
consistent with the idea that the nonamer epitope binds
much better to H-2Kb than the 8-mer epitope (27).
Combination Therapy Evokes Different Responses in Prophy-
lactic or Therapeutic Setting. Applying combination treatment
in mice depleted of different lymphoid populations, we
compared the requirements for successful B16 rejection in
a prophylactic setting and a therapeutic setting. In the ther-
apeutic setting, immunity to B16 tumors was found to be
critically dependent on CD8  T cells and to a lesser extent
on NK1.1  cells. In contrast, prophylactic combination treat-
ment induced sufficient protection to a subsequent B16
challenge in the absence of CD4, CD8, or NK1.1  cells.
However, autoimmune depigmentation still required CD8 
T cells. One interpretation could be that compared with
prophylaxis, in the therapeutic setting a more vigorous
CTL response is required to fight progressive disease. This
suggests that successful treatment of B16 is accompanied by
an enhanced risk of concomitant autoimmunity, and that
the window between antitumor immunity and autoimmu-
nity will be different in tumor-free or tumor-bearing sub-
jects (38). These observed differences in requirements for
lymphoid subpopulations may also explain discrepancies
with respect to the mechanism required for immunity to
B16 as described by others. A clear involvement of CD4 
T cells in control of B16 tumors was demonstrated earlier
(16). Similarly, generation of anti–TRP-2 CTL by genetic
immunization required the presence of functional CD4 T
cell help, and did not depend on NK cells, Fas, or perforin
(29). These results were obtained in prophylactic studies,
and our results suggest that they might have led to different
conclusions in a setting of treatment. As the requirements
for lymphoid subpopulations when compared between the
prophylactic and the therapeutic setting were different,
studying the therapeutic model for T cell–dependent im-
munotherapy of B16 is highly valuable for further develop-
ment of strategies to immunotherapy of cancer in man.
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